Literature DB >> 19285060

Time-dependent vascular actions of cannabidiol in the rat aorta.

Saoirse E O'Sullivan1, Yan Sun, Andrew J Bennett, Michael D Randall, David A Kendall.   

Abstract

We have shown that the major active agent of Cannabis sativa, Delta(9)-tetrahydrocannabinol, activates peroxisome proliferator-activated receptor gamma [PPARgamma, O'Sullivan, S.E., Tarling, E.J., Bennett, A.J., Kendall, D.A., Randall, M.D., 2005c. Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem. Biophys. Res. Commun. 337, 824-831]. The aim of the present study was to investigate whether another pharmacologically active phytocannabinoid, cannabidiol, similarly activates PPARgamma. Functional vascular studies were carried out in rat aortae in vitro by myography. PPARgamma activation was investigated using reporter gene assays, a PPARgamma competition-binding assay and an adipogenesis assay. Cannabidiol caused time-dependent (over 2 h) vasorelaxation of pre-constricted aortae, sensitive to PPARgamma antagonism (GW9662, 1 microM) and super oxide dismutase inhibition. The vascular effects of cannabidiol were not affected by endothelial denudation, nitric oxide synthase inhibition, pertussis toxin, cannabinoid CB1 or cannabinoid CB2 receptor antagonism, or capsaicin pre-treatment. When aortae were contracted with U46619 in a Ca2+-free buffer, vasorelaxation to cannabidiol was substantially reduced. Furthermore, cannabidiol (1-30 microM) inhibited the contractile response to the re-introduction of Ca2+. In a reporter gene assay, cannabidiol increased the transcriptional activity of PPARgamma. Cannabidiol was also found to bind to PPARgamma and stimulate the differentiation of 3T3-L1 fibroblasts into adipocytes, a PPARgamma-mediated response. These results show that cannabidiol binds to and activates PPARgamma, which partially underlies the time-dependent vascular effects of cannabidiol. However, cannabidiol-induced vasorelaxation in the rat isolated aorta appears to be largely due to calcium channel inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285060     DOI: 10.1016/j.ejphar.2009.03.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  61 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Authors:  Khalid A Jadoon; Garry D Tan; Saoirse E O'Sullivan
Journal:  JCI Insight       Date:  2017-06-15

3.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

Authors:  Sarah K Walsh; Claire Y Hepburn; Kathleen A Kane; Cherry L Wainwright
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 5.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 6.  Role of cannabis in cardiovascular disorders.

Authors:  Hemant Goyal; Hamza H Awad; Jalal K Ghali
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 7.  Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

Authors:  George W Booz
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

8.  Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo.

Authors:  Venkatesh L Hegde; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

9.  Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure.

Authors:  Mahshid Hosseinzadeh; Sara Nikseresht; Fariba Khodagholi; Nima Naderi; Nader Maghsoudi
Journal:  J Mol Neurosci       Date:  2016-01-06       Impact factor: 3.444

Review 10.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.